Vered Stearns, MDBCRF :: Vered Stearns
...Vered Stearns, MDAssistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins School of Medicine, Baltimore, MD
The overall goal of Dr. Stearns'
work is to utilize molecular changes in breast tissue or fluid to determine the women at the highest risk for a future breast cancer.In addition, she
team want to develop specific interventions that will reverse the molecular changes and may prevent breast cancer
.Women who have had hormone receptor-positive, early-stage breast cancer may take an aromatase inhibitor, such as anastrozole (Arimidex), a drug that blocks the effects of estrogen in the body and decreases the risk of developing a new or recurrent breast cancer. Dr. Stearns
is conducting a preliminary study to help determine which women are most likely to benefit from anastrozole.She
suspects that anastrozole will be most effective in women whose blood levels of estrogen drop and whose normal breast tissues become less dense after six months of treatment.At the same time, she
colleagues are evaluating the effects of a cholesterol-lowering drug called a "statin," a drug that has shown significant promise for preventing hormone negative breast cancer, on similar markers.They will also study the effects of combining anastrozole and simvastatin.Finally, they are very interested in the effects of certain soy compounds on genes in breast tissue and plan several investigations in the laboratory.
Bio: Dr. Stearns completed a B.S. equivalent at the Sackler Faculty of Medicine, Tel-Aviv University, in Israel in 1989.After relocating to the United States, she completed her medical school training at the University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, where she received her M.D. in 1992.Dr. Stearns
Internal Medicine residency at Georgetown University Medical Center
in Washington, DC in 1995.She
subsequently completed a Medical Oncology Fellowship at Georgetown University and the Lombardi Cancer Center
developed interest in translational breast cancer research.Dr. Stearns joined the faculty at the Lombardi Cancer Center at the Georgetown University in 1999, and at the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan in 2001.In 2002, she joined the faculty at the Breast Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.She is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Stearns's
long-term research goal is to improve upon current practices by individualizing therapies for breast cancer
.While administering standard chemotherapy in the preoperative setting, she
examines molecular markers and functional imaging that may assist in early determination of sensitivity or resistance to treatments.The long-term goal is to add novel agents to standard regimens using surrogate markers as endpoints.The work is supported by the prestigious Damon Runyon Clinical Investigator Award and by the NCI
has also examined surrogate markers that may predict response to treatments that may prevent breast cancer
such as tamoxifen and anastrozole. Dr. Stearns is a member of a large group funded by the NIH/NIGMS to evaluate the role of genetic polymorphism in efficacy and safety to common breast cancer treatments such as tamoxifen.
Finally, Dr. Stearns
has spent considerable time focusing on improving the quality of life of women who have survived their breast cancer
and suffer bothersome hot flashes.